Nicholas Haft
Fondateur chez Delix Therapeutics, Inc.
Profil
Nicholas Haft is the founder of Delix Therapeutics, Inc. He is currently the Director at Arcos Ventures SPV LLC.
Previously, he served as the Independent Director at Finch Therapeutics Group, Inc. from 2020 to 2023.
He completed his undergraduate degree at The Wharton School of the University of Pennsylvania.
Postes actifs de Nicholas Haft
Sociétés | Poste | Début |
---|---|---|
Delix Therapeutics, Inc.
Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | Fondateur | - |
Arcos Ventures SPV LLC | Directeur Général | 01/04/2015 |
Anciens postes connus de Nicholas Haft
Sociétés | Poste | Fin |
---|---|---|
FINCH THERAPEUTICS GROUP, INC. | Directeur/Membre du Conseil | 23/06/2023 |
Formation de Nicholas Haft
The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
FINCH THERAPEUTICS GROUP, INC. | Health Services |
Entreprise privées | 2 |
---|---|
Delix Therapeutics, Inc.
Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | Health Technology |
Arcos Ventures SPV LLC |